Home » Stocks » International Stem Cell

International Stem Cell Corporation (ISCO)

Stock Price: $0.680 USD 0.050 (7.94%)
Updated Aug 11, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 5.13M
Revenue (ttm) 9.61M
Net Income (ttm) -3.73M
Shares Out 7.54M
EPS (ttm) -0.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $0.680
Previous Close $0.630
Change ($) 0.050
Change (%) 7.94%
Day's Open 0.680
Day's Range 0.630 - 0.680
Day's Volume 4,414
52-Week Range 0.270 - 1.200

More Stats

Market Cap 5.13M
Enterprise Value 8.24M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 7.54M
Float 3.23M
EPS (basic) -0.5
EPS (diluted) -0.49
FCF / Share -0.13
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta 1.14
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.53
PB Ratio n/a
Revenue 9.61M
Operating Income -4.69M
Net Income -3.73M
Free Cash Flow -953,000
Net Cash -3.11M
Net Cash / Share -0.41
Gross Margin 57.61%
Operating Margin -48.81%
Profit Margin -38.80%
FCF Margin -9.91%
ROA -25.37%
ROE -160.76%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$81.00*
Low
81.0
Current: $0.680
High
81.0
Target: 81.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue9.4711.097.467.177.557.026.154.574.531.57
Revenue Growth-14.58%48.73%4.06%-5.11%7.61%14.15%34.6%0.77%189.03%-
Gross Profit5.547.025.335.225.505.104.503.302.910.84
Operating Income-5.73-3.47-4.94-4.85-4.56-8.68-7.55-9.82-11.36-10.46
Net Income-4.27-2.13-6.07-1.08-2.64-12.48-10.48-9.83-9.17-12.72
Shares Outstanding7.516.394.163.191.981.290.820.570.520.46
Earnings Per Share-0.57-0.33-1.46-0.34-2.26-10.34-13.49-19.49-17.99-31.48
Operating Cash Flow-1.40-1.08-2.14-4.20-4.12-6.42-5.64-6.69-6.96-6.95
Capital Expenditures-0.16-0.19-0.11-0.23-0.04-0.29-0.17-0.19-0.57-0.30
Free Cash Flow-1.56-1.27-2.25-4.43-4.16-6.70-5.81-6.88-7.53-7.25
Cash & Equivalents0.481.080.300.110.531.162.290.651.345.78
Total Debt3.462.05-------0.25
Net Cash / Debt-2.97-0.970.300.110.531.162.290.651.345.53
Assets6.627.806.867.057.147.187.745.375.749.93
Liabilities5.215.264.803.605.546.8611.967.132.114.54
Book Value-2.892.542.063.441.590.32-4.22-1.763.625.39
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name International Stem Cell Corporation
Country United States
Employees 39
CEO Andrey Semechkin

Stock Information

Ticker Symbol ISCO
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: ISCO

Description

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.